Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:VKTX News 19 October 2025 - 14 January 2026

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Legend Biotech fell 12.8% to a new 52-week low Monday, leading U.S. stock declines as the S&P 500 hovered just below record highs ahead of the Fed’s rate decision. Marvell Technology dropped 8.6%, Unilever ADR lost 7%, and several others slid 4–6%. Traders priced in an 85–90% chance of a 25-basis-point Fed rate cut this week.
8 December 2025
············
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics shares closed at $38.55 on December 5, 2025, with a market cap near $4.4 billion and analyst targets in the $80–$100 range. The stock is down 27% from its 52-week high but up 34% over three months, driven by late-stage obesity drug trials. Short interest stands at 22–24%. VK2735, its lead obesity candidate, remains in advanced development.
7 December 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying a market capitalization of roughly $3.9 billion. Stock Titan Shares sit well below their 52‑week high of $56.25, but far above the 52‑week low of $18.92, underscoring how volatile the weight‑loss drug trade has become. Investing.com+1 With Phase 3 trials
25 November 2025
··
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom What’s happening today (Nov. 11) Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025
11 November 2025
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursdayir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcementts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff. Since that rout,
19 October 2025
··

Stock Market Today

Ashtead Group share price ends week higher as U.S. listing clock ticks — what to watch next

Ashtead Group share price ends week higher as U.S. listing clock ticks — what to watch next

8 February 2026
Ashtead Group shares closed up 1.1% at 4,936 pence Friday after the company confirmed a new round of share buybacks. The firm expects its U.S. listing to become effective Feb. 26, with a UK share swap on Feb. 27 and new shares trading March 2. FTSE Russell plans to remove Ashtead from its UK indexes from March 2. Index funds are preparing for the change as the company shifts its primary listing to New York.
Beazley share price sits below Zurich’s £8bn offer — what to watch before London reopens

Beazley share price sits below Zurich’s £8bn offer — what to watch before London reopens

8 February 2026
Beazley shares closed flat at 1,236 pence Friday as Zurich faces a Feb. 16 deadline to make a firm takeover offer or withdraw. Zurich and Beazley have agreed in principle on key terms valuing Beazley at up to 1,335 pence per share. Recent filings show Vanguard and FMR LLC among top shareholders. The shares remain below the possible offer price as due diligence continues.
Tesco share price: what to watch after Friday’s close as rate and wage bets shift

Tesco share price: what to watch after Friday’s close as rate and wage bets shift

8 February 2026
Tesco shares closed at 452.10 pence on Friday, up 0.62%, as UK markets ended the week higher. Investors weighed Bank of England signals on interest rates and rising supermarket wage costs, with Lidl and rivals announcing pay increases ahead of April’s minimum wage hike. Morrisons is considering raising up to £1 billion against its store portfolio, according to Sky News. Tesco continues its share buyback program after a January profit forecast upgrade.
Imperial Brands share price: what to watch before IMB reopens after Friday jump

Imperial Brands share price: what to watch before IMB reopens after Friday jump

8 February 2026
Imperial Brands shares closed Friday up 1.49% at 3,341 pence, ahead of the Feb. 19 ex-dividend date and ongoing buybacks. The company repurchased 88,533 shares last week as part of a £1.45 billion program. Investors are watching interest rate signals and sector competition in nicotine pouches. British American Tobacco reports results Feb. 12.
Go toTop